Familial Hypercholesterolemia in the Finnish North Karelia
- 1 November 1997
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (11) , 3127-3138
- https://doi.org/10.1161/01.atv.17.11.3127
Abstract
A specific mutation termed FH-North Karelia [FH-NK] accounts for almost 90% of familial hypercholesterolemia [FH] cases in the Finnish North Karelia, with a population of about 180 000. Extensive search for its presence in the entire North Karelia province revealed 340 carriers of this mutation. Other mutations of the LDL receptor [LDLR] gene accounted for 67 cases of heterozygous FH. This gives a minimum FH prevalence of 1 in 441 inhabitants in North Karelia, with the highest density of patients in the Polvijärvi commune (1 in 143 inhabitants). Old parish records, confirmation records, and tax records were used to track a common ancestor for most of the present-day North Karelian FH-NK patients in the village of Puso, located within an area where the FH prevalence today is the highest. DNA analysis indicated that 2% of the subjects aged 1 to 25 years would have been diagnosed as false-negative and 7% as false-positive FH patients on the basis of LDL cholesterol [LDL-C] determinations alone. Common genetic variations of apolipoprotein E [apoE],XbaI, polymorphism of apolipoprotein B [apoB], andPvuII polymorphism of the intact LDLR allele contributed little to serum lipid variation in established carriers of the FH-NK allele, although apoE2/4 genotype and the presence of thePvuII restriction site tended to be associated with relatively low LDL-C levels. Coronary heart disease (CHD) was present in 65 (30%) out of the 179 FH gene carriers aged ≥25 years, and 19 individuals had a previous history of acute myocardial infarction (AMI). The average age (mean±SD) at onset of CHD was 42±7 years for males and 48±11 years for females (P<.05). In stepwise logistic regression analysis carried out in carriers of the FH-NK allele, age, gender, smoking, and apoE allele E2 all emerged as independent determinants of risk of CHD or AMI. It may be concluded that the relatively high prevalence of FH patients in North Karelia province provides a unique founder population in which genetic and nongenetic factors modifying the course of FH can be effectively investigated.Keywords
This publication has 34 references indexed in Scilit:
- Homozygous familial hypercholesterolemia: A paradigm for phenotypic variationThe American Journal of Cardiology, 1993
- Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemiaAtherosclerosis, 1993
- Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapyJournal of Internal Medicine, 1993
- Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemiaAtherosclerosis, 1993
- The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland.Journal of Clinical Investigation, 1992
- Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1990
- Apolipoprotein E phenotype and cholesterol metabolism in familial hypercholesterolemiaAtherosclerosis, 1989
- Deletion in the Gene for the Low-Density-Lipoprotein Receptor in a Majority of French Canadians with Familial HypercholesterolemiaNew England Journal of Medicine, 1987
- Coronary artery disease in heterozygous familial hypercholesterolemiaAtherosclerosis, 1982
- Heterozygous familial hypercholesterolemiaAtherosclerosis, 1979